AMLN

AMLN Articles

What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to wonder which other peers and competitors might be on the M&A block. Monday’s...
More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks associated with future regulation under health care, but deals in the biotech and emerging...
Source: Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Tuesday.ADTRAN Inc. (NASDAQ: ADTN) Cut to Equal-weight at...
The freshly announced multibillion biotech buyout of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) for more than $5 billion in equity value may be a bit misleading if you consider that it is...
As of late last week we had many potentially imminent buyouts that could have hit the market.  When we were just finishing the report draft on Friday is when the Amylin Pharmaceuticals, Inc....
Some mergers are very straight-forward, and others are just odd.  Now we have an answer over whether or not Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) was going to be acquired or not. ...
Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is back in the rumor mill as far as a buyout, but this time the price appears to be more finite.  We have heard enough names around this diabetes treatment...
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) is supposed to be acquired by a larger drug company.  It is one of the biggest public merger rumors out there. At least that is the belief of Wall...
Amylin Pharmaceuticals, Inc. (AMLN) is supposed to be getting a takeover offer soon, or at least it is expected to receive or disclose several possible bids soon.  Now the company has one more bit...
Markets opened lower this morning following some reversals in Europe, not the least of which is the coming French presidential election. PMI readings from Europe and China were also weak. Asian and...
Ardea Biosciences, Inc. (NASDAQ: RDEA) is soaring today on news that AstraZeneca PLC (NYSE: AZN) is paying about $1.26 billion to acquire the company.  With another small-cap to mid-cap biotech and...
Diabetes drug maker Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) has hired bankers and lawyers to help the company find a buyer. In February Amylin turned down a $3.5 billion ($22/share) offer from...
After legal issues slowed their progress last year, foreclosures are about to increase. (Reuters)Time Warner Cable (NYSE: TWC) may end its deal with Current TV because of low ratings. (Reuters)The...
Markets opened nearly flat this morning but took a dive early and have muddled along the rest of the day in negative territory. This morning’s report on falling durable goods orders got things off...
If there was a merger candidate which ever made sense in biotech and pharma it is Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN).  News from Bloomberg is out that the company has rejected an offer to...